COMP <GO>
LFMD vs JNJ // EV/EBITDA & P/E VALUATION
LifeMD Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LFMD 4
— JNJ 7
■ METRIC PARITY
LAST: $2.32 (+4.04%) • MKT CAP: $111.8M
valuation
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.70% | 67.90% | +17.80 | LFMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -26.20% | 25.50% | -51.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.73% | 2.97% | +2.76 | LFMD | /fcf-yield <GO> |
| Operating Margin | -4.00% | 34.70% | -38.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -5.80% | 28.50% | -34.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 25.30% | 6.00% | +19.30 | LFMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.78% | 0.00% | +2.78 | LFMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.8 | 62.1 | -23.35 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $111.8M | $662.49B | -$662.38B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFMD REV | JNJ REV | LFMD GROSS % | JNJ GROSS % | LFMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $194.1M | $94.19B | 85.7% | 67.9% | $6.4M | $19.70B |
| FY 2024 | $154.8M | $88.82B | 86.2% | 69.1% | $16.0M | $19.84B |
| FY 2023 | $152.5M | $85.16B | — | — | $8.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFMD // BETA —
JNJ // BETA 1.08